19.62
0.15%
-0.17
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$19.79
Aprire:
$19.85
Volume 24 ore:
37,865
Relative Volume:
0.03
Capitalizzazione di mercato:
$1.65B
Reddito:
$288.00K
Utile/perdita netta:
$-228.06M
Rapporto P/E:
-4.0287
EPS:
-4.87
Flusso di cassa netto:
$-168.82M
1 W Prestazione:
-8.69%
1M Prestazione:
-19.58%
6M Prestazione:
+53.42%
1 anno Prestazione:
+25.86%
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Nome
Viridian Therapeutics Inc
Settore
Industria
Telefono
617.272.4600
Indirizzo
221 CRESCENT STREET, WALTHAM
Confronta VRDN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
VRDN | 19.59 | 1.65B | 288.00K | -228.06M | -168.82M | -4.87 |
VRTX | 446.42 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 739.53 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 587.24 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.48 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-06-14 | Iniziato | BTIG Research | Buy |
2023-06-14 | Ripresa | Credit Suisse | Outperform |
2023-05-30 | Iniziato | RBC Capital Mkts | Outperform |
2023-04-17 | Iniziato | Wells Fargo | Overweight |
2023-03-30 | Iniziato | Stifel | Buy |
2022-12-19 | Iniziato | Cowen | Outperform |
2022-12-19 | Iniziato | Needham | Buy |
2022-12-16 | Iniziato | Credit Suisse | Outperform |
2022-12-01 | Iniziato | H.C. Wainwright | Buy |
2022-06-23 | Iniziato | B. Riley Securities | Buy |
2021-11-18 | Iniziato | SVB Leerink | Outperform |
2021-10-12 | Iniziato | Evercore ISI | Outperform |
2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
B. Riley Has Bearish Forecast for VRDN FY2024 Earnings - MarketBeat
10 Best Small-Cap Stocks Ready To Explode - Insider Monkey
Viridian Therapeutics, Inc. (VRDN): This Small-Cap Stock Is Ready To Explode - Insider Monkey
Viridian Therapeutics (VRDN) Has Captured Investors’ Attention with Recent Breakthroughs - Nasdaq
HC Wainwright Has Bullish Forecast for VRDN FY2024 Earnings - MarketBeat
Viridian Therapeutics’ (VRDN) Buy Rating Reiterated at Needham & Company LLC - Defense World
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $34.00 - Defense World
FY2024 EPS Forecast for Viridian Therapeutics Cut by Analyst - Defense World
What is Lifesci Capital’s Estimate for VRDN FY2024 Earnings? - Defense World
What is Leerink Partnrs’ Forecast for VRDN FY2024 Earnings? - Defense World
(VRDN) Trading Signals - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5.8%Should You Sell? - MarketBeat
Perceptive Advisors LLC's Strategic Acquisition in Viridian Ther - GuruFocus.com
Paradigm Biocapital Advisors LP Increases Stake in Viridian Ther - GuruFocus.com
Wedbush Has Pessimistic Outlook of VRDN FY2024 Earnings - MarketBeat
Leerink Partnrs Has Pessimistic View of VRDN FY2024 Earnings - MarketBeat
Lifesci Capital Has Bearish Outlook for VRDN FY2024 Earnings - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Viridian Therapeutics Inc (VRDN) Quarterly 10-Q Report - Quartzy
Q1 Earnings Estimate for VRDN Issued By Wedbush - MarketBeat
HC Wainwright Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - MarketBeat
Viridian Therapeutics stock target upgraded, keeps buy on veligrotug outlook By Investing.com - Investing.com Canada
Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate - Simply Wall St
In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics - Benzinga
Viridian Therapeutics (NASDAQ:VRDN) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Viridian Therapeutics Reports Increased Cash Reserves Amid Losses - TipRanks
Viridian Therapeutics Reports Third Quarter 2024 Financial Results - citybiz
Viridian Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Viridian Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - XM
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Viridian Therapeutics earnings missed by $0.09, revenue fell short of estimates - Investing.com UK
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data - Yahoo Finance
Stifel raises Viridian Therapeutics target to $41, keeps buy rating By Investing.com - Investing.com UK
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 1-Year HighTime to Buy? - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Grants 150K Stock Options to New Employees in Retention Push | VRDN Stock News - StockTitan
(VRDN) Long Term Investment Analysis - Stock Traders Daily
Net Present Value Model: Viridian Therapeutics Inc’s Veligrotug - GlobalData
Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings - Yahoo Finance
Analyst Expectations For Viridian Therapeutics's Future - Fidelity Investments
Needham & Company LLC Reaffirms Buy Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Position Boosted by Novo Holdings A S - MarketBeat
How To Trade (VRDN) - Stock Traders Daily
VRDN Factor-Based Stock Analysis - Nasdaq
Viridian Therapeutics' Superior Prospects Make It A Buy (NASDAQ:VRDN) - Seeking Alpha
Viridian Therapeutics (VRDN): A Small-Cap Biotech with Promising Clinical Results - Insider Monkey
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
SG Americas Securities LLC Has $374,000 Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
State Street Corp's Strategic Reduction in Viridian Therapeutics Inc - Yahoo Finance
Viridian Therapeutics Inc Azioni (VRDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):